Global Footprint Sequentia Biotech serves clients in many countries across diagnostics, drug discovery, medical and academic research, plant biology, and food technologies, indicating a broad, multi-vertical sales opportunity. This global footprint enables cross-sell and multi-region deployments of its SaaS analytics suite to large biotech firms, CROs, and research institutions.

Omics Platform Portfolio Their SaaS stack includes AIR, GINO, GAIA and the MICK microbiome platform, offering analytics across transcriptomics, genomics, metagenomics and health applications. This diversified portfolio supports targeted pitches to different buyer personas such as clinical labs, pharma companies and academic researchers, with potential for bundled licenses or pilots.

Partnerships and Integrations Strategic partnerships like the integration with Platomics for regulatory workflows create a compelling proposition for customers needing end-to-end data management and compliance. Position Sequentia as a co-sell partner for data analytics plus regulatory data handling, and highlight potential integrations with clients’ LIMS and data pipelines to shorten time-to-insight.

Growth Momentum Growth momentum is underscored by recent financing, a high-profile regional recognition, and strategic acquisitions. Use this credibility to pursue enterprise contracts, multi-year licenses, and co-development engagements with pharma, biotech firms and research institutions.

Health Sector Focus With a focus on diagnostics, drug discovery, medical and academic research plus plant biology and food technologies, Sequentia Biotech can pursue targeted outreach to CROs, pharmaceutical companies, and university labs needing omics analytics, microbiome insights, and regulatory-ready data workflows. Emphasize microbiome health use cases and translational research to differentiate from competitors.